FDA finalises guidance on its postmarketing safety surveillance

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2024年 / 1995卷 / 1期

关键词：

D O I：

10.1007/s40278-024-53265-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：2 / 2

相关论文

共 50 条

[1] US FDA enhancing postmarketing drug safety surveillance
[J]. Reactions Weekly, 2019, 1780 (1) : 3 - 3
[2] US FDA Enhancing Postmarketing Drug Safety Surveillance
不详
[J]. PHARMACEUTICAL MEDICINE, 2020, 34 (01) : 64 - 64
[3] FDA will increase postmarketing surveillance of drugs
Tanne, JH
[J]. BRITISH MEDICAL JOURNAL, 2004, 329 (7476): : 1203 - 1203
[4] US FDA posts report on postmarketing surveillance
[J]. Reactions Weekly, 2019, 1766 (1) : 3 - 3
[5] Postmarketing surveillance for drug safety
Holden, WL
Scarazzini, LJ
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (05) : 503 - 503
[6] POSTMARKETING SURVEILLANCE OF THE SAFETY OF CIMETIDINE
CROMBIE, IK
[J]. BRITISH MEDICAL JOURNAL, 1983, 286 (6383): : 2062 - 2062
[7] US FDA, EMEA look to harmonise postmarketing surveillance
[J]. Reactions Weekly, 2007, 1152 (1) : 2 - 2
[8] How to get the data? Scrutiny of postmarketing surveillance at the FDA
不详
[J]. HEALTH AFFAIRS, 2005, 24 (04) : 927 - 927
[9] US FDA addresses postmarketing drug surveillance concerns
[J]. Reactions Weekly, 2004, 1030 (1) : 3 - 3
[10] Nimotuzumab Cuban Safety Postmarketing Surveillance
P. Piedra Sierra
G. Saurez Martinez
A. Bencomo Yánez
Y. Pomares Iturralde
Md. C. Barroso Alvarez
N. Iznaga Escobar
[J]. Drug Safety, 2008, 31 : 885 - 885

← 1 2 3 4 5 →